Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

Bertrand Tombal, Fred Saad, David F. Penson, Maha Hussain, Cora N. Sternberg, Robert Morlock, Krishnan Ramaswamy, Cristina Ivanescu, Gerhardt Attard

The Lancet Oncology · 2019 · 106 citations · 28 references

DOIFull text

Open access

Concepts

References

28